This week in drug discovery (9-13 October)
News round-up for 9-13 October by DDW Digital Content Editor Diana Spencer.
The buzz with week has been around Phase I trials, with new therapies for lung cancer, geographic atrophy, Parkinson’s, sarcopenia and long Covid demonstrating positive early results or entering clinical trials for the first time.
The top stories:
Non-viral gene therapy shows early efficacy in lung cancer
Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC).
Advancing therapeutics to delay the onset of age-related diseases
Rejuvenate Biomed, a clinical-stage company advancing therapeutics to delay the onset of age-related diseases, has completed a six-week clinical proof-of-mechanism study with lead candidate RJx-01 for the treatment of sarcopenia.
Antibody treatment for geographic atrophy enters clinical trials
Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA).
Allosteric therapy targets common genetic cause of Parkinson’s
Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease.
Could a common antiviral treat long Covid?
A UK-based study will investigate whether a common anti-viral medication could double up as a treatment for long Covid.